BS-181CDK7 inhibitor,highly selective CAS# 1092443-52-1 |
- LY2835219
Catalog No.:BCC1113
CAS No.:1231930-82-7
- Roscovitine (Seliciclib,CYC202)
Catalog No.:BCC1105
CAS No.:186692-46-6
- Nu 6027
Catalog No.:BCC1154
CAS No.:220036-08-8
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- AT7519 Hydrochloride
Catalog No.:BCC1376
CAS No.:902135-91-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1092443-52-1 | SDF | Download SDF |
| PubChem ID | 49867929 | Appearance | Powder |
| Formula | C22H32N6 | M.Wt | 380.53 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (131.40 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 5-N-(6-aminohexyl)-7-N-benzyl-3-propan-2-ylpyrazolo[1,5-a]pyrimidine-5,7-diamine | ||
| SMILES | CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)NCCCCCCN | ||
| Standard InChIKey | DNYBIOICMDTDAP-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H32N6/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22(19)28)24-13-9-4-3-8-12-23/h5-7,10-11,14,16-17,25H,3-4,8-9,12-13,15,23H2,1-2H3,(H,24,27) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | BS-181 is a highly selective CDK7 inhibitor with IC50 of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.In Vitro:BS-181 promotes cell cycle arrest and inhibits cancer cell growth, and growth is inhibited for all cell lines tested, with IC50 values ranging from 11.5 to 37 μM. BS-181 inhibits RB phosphorylation at Ser795 and Ser821 with an apparent IC50 of 15 μM, similar to the IC50 obtained for P-Ser2 inhibition. BS-181 treatment of MCF-7 cells leads to G1 arrest at and apoptosis[1]. BS-181 inhibits GC cell and normal gastric epithelial RGM-1 cell line growth with inhibitory concentration (IC50) ranging from 17 to 22 μM and 6.5 μM, respectively. BS-181 significantly inhibits cell migration and invasion ability in a dose-dependent manner[2].In Vivo:BS-181 (5 mg/kg, 10 mg/kg, i.p.) inhibits the growth of MCF-7 tumors in nude mice. Intravenous (i.v) and i.p administration of 10 mg/kg BS-181 shows rapid clearance[1]. BS-181 (10 mg/kg/d or 20 mg/kg/d, i.p.) significantly inhibits the growth of tumor in a dose-dependent manner compared to the control group[2]. References: | |||||
BS-181 Dilution Calculator
BS-181 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6279 mL | 13.1396 mL | 26.2791 mL | 52.5583 mL | 65.6978 mL |
| 5 mM | 0.5256 mL | 2.6279 mL | 5.2558 mL | 10.5117 mL | 13.1396 mL |
| 10 mM | 0.2628 mL | 1.314 mL | 2.6279 mL | 5.2558 mL | 6.5698 mL |
| 50 mM | 0.0526 mL | 0.2628 mL | 0.5256 mL | 1.0512 mL | 1.314 mL |
| 100 mM | 0.0263 mL | 0.1314 mL | 0.2628 mL | 0.5256 mL | 0.657 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Normal progression through the cell cycle requires the sequential action of cyclin-dependent kinases (CDK1, CDK2, CDK4 and CDK6). Deregulation of CDK activity is a feature of almost all cancers and has led to the development of CDK inhibitors as anticancer agents. As such, CDK7 is an target for the anticancer drug development. Computer modeling of CDK7 was used to design potential potent CDK7 inhibitor, which is BS-181.
In vitro: Testing of other CDKs as well as another 69 kinases showed that BS-181 only inhibited CDK2 at concentrations lower than 1 μM, with 35-fold less potently (IC50 880 nM) than CDK7. BS-181 inhibited the phosphorylation of CDK7 substrates in MCF-7 cells, led to cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines, and showed antitumor effects in vivo [1].
In vivo: BS-181 was stable in vivo after i.p. administration of 10 mg kg-1. The same dose of drug inhibited the growth of MCF-7 human xenografts in nude mice. BS-181 is the first example of a potent and selective CDK7 inhibitor with potential as an anticancer agent [1].
Clinical trial: Currently no clinical data are available.
Reference:
[1] Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AG, Coombes RC. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009;69(15):6208-15.
- 3Beta-Isodihydrocadambine 4-oxide
Catalog No.:BCN3651
CAS No.:1092371-18-0
- Poziotinib
Catalog No.:BCC6380
CAS No.:1092364-38-9
- PP242
Catalog No.:BCC3682
CAS No.:1092351-67-1
- PSB 603
Catalog No.:BCC7598
CAS No.:1092351-10-4
- Camellianin A
Catalog No.:BCN7864
CAS No.:109232-77-1
- ent-11beta-Hydroxyatis-16-ene-3,14-dione
Catalog No.:BCN6600
CAS No.:1092103-22-4
- 3,4,5-Trimethoxyphenyl-(6-O-galloyl)-O-beta-D-glucopyranoside
Catalog No.:BCN7272
CAS No.:109206-94-2
- Tachioside
Catalog No.:BCN5884
CAS No.:109194-60-7
- Boc-Chg-OH
Catalog No.:BCC3163
CAS No.:109183-71-3
- 2-(Chloromethyl)-4-methylquinazoline
Catalog No.:BCC8482
CAS No.:109113-72-6
- Icariside B1
Catalog No.:BCN7271
CAS No.:109062-00-2
- Schizanthine E
Catalog No.:BCN1937
CAS No.:109031-04-1
- NVP-BSK805
Catalog No.:BCC1815
CAS No.:1092499-93-8
- Deuterated Atazanivir-D3-2
Catalog No.:BCC2116
CAS No.:1092540-51-6
- Deuterated Atazanivir-D3-3
Catalog No.:BCC2117
CAS No.:1092540-52-7
- Deuterated Atazanivir-D3-1
Catalog No.:BCC2115
CAS No.:1092540-56-1
- Paxiphylline D
Catalog No.:BCN5885
CAS No.:1092555-02-6
- Paxiphylline E
Catalog No.:BCN5886
CAS No.:1092555-03-7
- (3R,4S)-Tofacitinib
Catalog No.:BCC4268
CAS No.:1092578-46-5
- (3S,4S)-Tofacitinib
Catalog No.:BCC4052
CAS No.:1092578-47-6
- (3S,4R)-Tofacitinib
Catalog No.:BCC4267
CAS No.:1092578-48-7
- WAY 100635 hydrochloride
Catalog No.:BCC5061
CAS No.:146714-97-8
- IT1t dihydrochloride
Catalog No.:BCC6234
CAS No.:1092776-63-0
- PP121
Catalog No.:BCC4980
CAS No.:1092788-83-4
Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.[Pubmed:27042010]
Drug Des Devel Ther. 2016 Mar 16;10:1181-9.
Cyclin-dependent kinase (CDK) family members have been considered as attractive therapeutic targets for cancer. In this study, we aim to investigate the anticancer effects of a selective CDK7 inhibitor, BS-181, in gastric cancer (GC) cell line. Human GC cells (BGC823) were cultured with or without BS-181 at different concentrations for 24-72 hours. BS-181 significantly reduced the activity of CDK7 with downregulation of cyclin D1 and XIAP in GC cells. Treatment with BS-181 induced cell cycle arrest and apoptosis. The expression of Bax and caspase-3 was significantly increased, while Bcl-2 expression was decreased in cells treated with BS-181. In addition, the inhibition of CDK7 with BS-181 resulted in reduced rates of proliferation, migration, and invasion of gastric cells. Those results demonstrated the anticancer activities of selective CDK7 inhibitor BS-181 in BGC823 cells, suggesting that CDK7 may serve as a novel therapeutic target or the treatment of GC.
